Publicaciones de prensa

Back to previous page

ReGen Biologics Enters New Markets in Poland and South Africa

Hackensack, NJ – November 21, 2007 – ReGen Biologics (OTC: RGBI) recently initiated marketing for its products, including the CMI^® collagen meniscus implant in Poland and in South Africa.

The market introduction in Poland occurred on November 12 with three surgeries completed on two patients in the “Centrum Medycyny Sportowej” in Warsaw.  The surgeries were performed by Dr. Konrad Slynarski, assisted by Dr. William Rodkey, D.V.M., Vail, Colorado.  ReGen will be working with Biocare Therapeutics Sp. z.o.o. in Poznan to train surgeons and market the CMI throughout Poland.

In addition, twenty leading knee surgeons from South Africa attended a CMI training event on November 16 at the Sports Science Institute of South Africa in Cape Town. Training was conducted by Dr. Koen Lagae from Antwerp, Belgium and Dr. William Rodkey.  Following the training activities the same group observed five live CMI surgeries, which were performed at the “Vincent Palotti Hospital” in Cape Town by Dr. Koen Lagae and by the local host Dr. Willem van der Merwe, again assisted by Dr. Rodkey.

ReGen will be working with Doc Medical Solutions, located at the Sport Science Institute in Cape Town, to train surgeons and market the CMI throughout South Africa.  

“We are pleased to make our CMI collagen meniscus implant available to patients and surgeons in Poland and South Africa, representing a combined population of 90 million people,” commented Marcel Kyburz, General Manager of ReGen Biologics AG.

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery.  ReGen’s first approved product using its collagen scaffold technology is the CMI^® meniscus application, which is cleared for sale in Europe and other countries and marketed through ReGen’s European subsidiary, ReGen Biologics AG.

ReGen has conducted the largest human clinical trial on an arthroscopic meniscus procedure.  The resulting database has unique value in better understanding meniscus injuries.  The company is headquartered in Hackensack, NJ and manufactures its products in its ISO Certified facility located in Redwood City, CA.  For more information on ReGen, visit www.regenbio.com .

Contacts:
Brion Umidi
ReGen Biologics, Inc.
Chief Financial Officer
(201) 651-3515
bumidi@regenbio.com

Marcel Kyburz
ReGen Biologics AG
General Manager
+41 (0) 79 341 28 82
marcel.kyburz@regenbio.com

Poland
Biocare Therapeutics Sp. z.o.o.
+48 (0) 61 822 2418
bmarczyk@biocare.pl

South Africa
Doc Medical Solutions
+27 (0) 21 686 1196
dionoc@mweb.co.za

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2006 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services and at the Web site maintained by the SEC at http://www.sec.gov .